$INAB
IN8BIO, INC.

2021 Q3 Form 10-Q Financial Statement

#000095017021001767 Filed on September 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.041M $2.103M $3.179M
YoY Change 92.94% 17.39%
% of Gross Profit
Research & Development $1.350M $2.064M
YoY Change 27.72% 15.7%
% of Gross Profit
Depreciation & Amortization $22.00K $22.00K $44.00K
YoY Change 0.0% 0.0% -4.35%
% of Gross Profit
Operating Expenses $3.391M $3.050M $8.557M
YoY Change 101.73% 6.12% 68.91%
Operating Profit -$3.391M -$3.050M
YoY Change 101.73% 6.12%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.391M -$5.413M -$8.557M
YoY Change 88.34% 66.67%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.391M -$3.050M -$8.557M
YoY Change 101.73% 6.12% 66.67%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$1.00
Diluted Earnings Per Share -$180.8K -$1.00 -$456.3K
COMMON SHARES
Basic Shares Outstanding 18.75M 3.764M
Diluted Shares Outstanding 13.38M 3.764M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.68M $12.00M $17.99M
YoY Change 277.33%
Cash & Equivalents $40.68M $12.00M $17.99M
Short-Term Investments
Other Short-Term Assets $35.00K $168.0K $0.00
YoY Change 15.86%
Inventory
Prepaid Expenses $3.167M $150.0K
Receivables
Other Receivables
Total Short-Term Assets $43.88M $12.17M $18.14M
YoY Change 265.92%
LONG-TERM ASSETS
Property, Plant & Equipment $302.0K $142.0K $186.0K
YoY Change -38.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $409.0K $141.0K $0.00
YoY Change 53.26%
Total Long-Term Assets $3.257M $5.397M $2.766M
YoY Change 1576.09%
TOTAL ASSETS
Total Short-Term Assets $43.88M $12.17M $18.14M
Total Long-Term Assets $3.257M $5.397M $2.766M
Total Assets $47.13M $17.56M $20.91M
YoY Change 381.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $692.0K $462.0K $620.0K
YoY Change -17.65%
Accrued Expenses $840.0K $1.485M $1.778M
YoY Change 18.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $464.0K $691.0K $174.0K
YoY Change 1091.38%
Total Short-Term Liabilities $2.160M $2.773M $2.572M
YoY Change 48.53%
LONG-TERM LIABILITIES
Long-Term Debt $343.0K $432.0K $0.00
YoY Change 272.41%
Other Long-Term Liabilities $1.593M $698.0K $0.00
YoY Change -15.8%
Total Long-Term Liabilities $1.936M $1.130M $17.00K
YoY Change 19.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.160M $2.773M $2.572M
Total Long-Term Liabilities $1.936M $1.130M $17.00K
Total Liabilities $4.096M $3.903M $2.589M
YoY Change 38.8%
SHAREHOLDERS EQUITY
Retained Earnings -$26.84M -$23.45M -$18.04M
YoY Change
Common Stock $3.000K $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $43.04M -$21.24M -$16.58M
YoY Change
Total Liabilities & Shareholders Equity $47.13M $17.56M $20.91M
YoY Change 381.6%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q4
OPERATING ACTIVITIES
Net Income -$3.391M -$3.050M -$8.557M
YoY Change 101.73% 6.12% 66.67%
Depreciation, Depletion And Amortization $22.00K $22.00K $44.00K
YoY Change 0.0% 0.0% -4.35%
Cash From Operating Activities -$6.365M -$2.461M -$3.868M
YoY Change 49.88% 39.24%
INVESTING ACTIVITIES
Capital Expenditures -$153.0K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$153.0K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 35.19M -592.0K 18.68M
YoY Change -481.94% 28641.54%
NET CHANGE
Cash From Operating Activities -6.365M -2.461M -3.868M
Cash From Investing Activities -153.0K 0.000 0.000
Cash From Financing Activities 35.19M -592.0K 18.68M
Net Change In Cash 28.68M -3.053M 14.81M
YoY Change 105.31% -644.03%
FREE CASH FLOW
Cash From Operating Activities -$6.365M -$2.461M -$3.868M
Capital Expenditures -$153.0K $0.00 $0.00
Free Cash Flow -$6.212M -$2.461M -$3.868M
YoY Change 49.88% 43.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 us-gaap Cash
Cash
17994000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
168000
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18754553
CY2021Q2 us-gaap Cash
Cash
11999000
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001740279
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39692
dei Entity Registrant Name
EntityRegistrantName
IN8BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5462585
dei Entity Address Address Line1
EntityAddressAddressLine1
79 Madison Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10016
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
600-6438
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
INAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
150000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
12167000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18144000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
186000
CY2021Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3362000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2439000
CY2021Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
990000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
762000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141000
CY2021Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
5397000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
2766000
CY2021Q2 us-gaap Assets
Assets
17564000
CY2020Q4 us-gaap Assets
Assets
20910000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
462000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
620000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1485000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1778000
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
517000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
135000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q2 us-gaap Loans Payable Current
LoansPayableCurrent
174000
CY2020Q4 us-gaap Loans Payable Current
LoansPayableCurrent
174000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2773000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2572000
CY2021Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17000
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
432000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
698000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q2 us-gaap Liabilities
Liabilities
3903000
CY2020Q4 us-gaap Liabilities
Liabilities
2589000
CY2021Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
27564260
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
27564260
CY2021Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
9993727
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
9993727
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
9993727
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
9993727
CY2021Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
39390000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
37969000
CY2021Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
34900000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
34900000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50700000
us-gaap Operating Expenses
OperatingExpenses
4565000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3050000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2874000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50700000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3764488
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3764488
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3764488
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3764488
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2211000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1458000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23451000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18038000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-21239000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16579000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17564000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20910000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2064000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1784000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3310000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2836000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
986000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1090000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2103000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1729000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
3050000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
2874000
us-gaap Operating Expenses
OperatingExpenses
5413000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5413000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4565000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3050000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2874000
us-gaap Net Income Loss
NetIncomeLoss
-5413000
us-gaap Net Income Loss
NetIncomeLoss
-4565000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.82
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3764488
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3462182
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3764488
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3383774
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-9242000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
200000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1691000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3483000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16579000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
361000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-10715000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2363000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-18581000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3050000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-21239000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2874000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-13569000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
392000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5854000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5995000
inab Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
1020000
inab Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0
us-gaap Profit Loss
ProfitLoss
-5413000
us-gaap Profit Loss
ProfitLoss
-4565000
us-gaap Depreciation
Depreciation
44000
us-gaap Depreciation
Depreciation
44000
us-gaap Share Based Compensation
ShareBasedCompensation
753000
us-gaap Share Based Compensation
ShareBasedCompensation
38000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
250000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
0
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
61000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
62000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-372000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-221000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1191000
inab Increase Decrease Short Term Operating Lease Liabilities
IncreaseDecreaseShortTermOperatingLeaseLiabilities
62000
inab Increase Decrease Short Term Operating Lease Liabilities
IncreaseDecreaseShortTermOperatingLeaseLiabilities
0
inab Increase Decrease Long Term Operating Lease Liabilities
IncreaseDecreaseLongTermOperatingLeaseLiabilities
-70000
inab Increase Decrease Long Term Operating Lease Liabilities
IncreaseDecreaseLongTermOperatingLeaseLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4968000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3284000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
200000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
5480000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
248000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
174000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
779000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1027000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2570000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17994000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
610000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11999000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3180000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and related valuation allowance, fair value of common stock and stock-based compensation, and the useful lives of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
443000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
443000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
301000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
257000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
186000
CY2021Q2 us-gaap Depreciation
Depreciation
22000
CY2020Q2 us-gaap Depreciation
Depreciation
22000
us-gaap Depreciation
Depreciation
44000
us-gaap Depreciation
Depreciation
44000
CY2021Q2 inab Accrued Offering Costs
AccruedOfferingCosts
806000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 inab Accrued Offering Costs
AccruedOfferingCosts
876000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3764488
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.02
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3764488
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3764488
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50700000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.96
CY2021Q2 inab Accrued Clinical Trials
AccruedClinicalTrials
300000
CY2020Q4 inab Accrued Clinical Trials
AccruedClinicalTrials
376000
CY2021Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
340000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
400000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
126000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1485000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1778000
inab Year Of Maturity
YearOfMaturity
2022
CY2020 inab Year Of Maturity
YearOfMaturity
2022
CY2021Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0100
CY2020Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0100
CY2021Q2 us-gaap Notes And Loans Payable
NotesAndLoansPayable
174000
CY2020Q4 us-gaap Notes And Loans Payable
NotesAndLoansPayable
174000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50700000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3764488
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1247158
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.16
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M2D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1486000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
305132
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.36
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1314118
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
238172
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M17D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
715000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1552290
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1486000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.64
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y1M24D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
771000
us-gaap Deferred Compensation Arrangement With Individual Maximum Contractual Term1
DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8878
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.833
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0067
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0045
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
392000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
753000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38000
us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2021Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2020Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
715000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3050000
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
304000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
1421000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
564000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3765000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2874000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3178000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6834000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5129000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.82
us-gaap Net Income Loss
NetIncomeLoss
-5413000
us-gaap Net Income Loss
NetIncomeLoss
-4565000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3764488
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3462182
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3764488
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3383774
inab Royalty Term
RoyaltyTerm
P10Y
CY2021Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
138000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
250000
CY2021Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
25000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
46000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
53000
us-gaap Operating Lease Cost
OperatingLeaseCost
105000
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
134000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
249000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2021Q2 us-gaap Lease Cost
LeaseCost
350000
us-gaap Lease Cost
LeaseCost
650000
CY2021Q2 inab Cash Paid For Amounts Included In Finance Leases
CashPaidForAmountsIncludedInFinanceLeases
340000
CY2021Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.102
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2021Q2 inab Cash Paid For Amounts Included In Operating Leases
CashPaidForAmountsIncludedInOperatingLeases
52000
CY2021Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M1D
CY2021Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
327000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
105000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
435000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
216000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
253000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
223000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
30000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
230000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
237000
CY2021Q2 inab Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
0
CY2021Q2 inab Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
41000
CY2021Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1045000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1052000
CY2021Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
96000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
219000
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
949000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
833000

Files In Submission

Name View Source Status
0000950170-21-001767-index-headers.html Edgar Link pending
0000950170-21-001767-index.html Edgar Link pending
0000950170-21-001767.txt Edgar Link pending
0000950170-21-001767-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img237016903_0.jpg Edgar Link pending
inab-20210630.htm Edgar Link pending
inab-20210630.xsd Edgar Link pending
inab-20210630ex31_1.htm Edgar Link pending
inab-20210630ex31_2.htm Edgar Link pending
inab-20210630ex32_1.htm Edgar Link pending
inab-20210630_cal.xml Edgar Link unprocessable
inab-20210630_def.xml Edgar Link unprocessable
inab-20210630_htm.xml Edgar Link completed
inab-20210630_lab.xml Edgar Link unprocessable
inab-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending